Tilray enters its fiscal first-quarter report with a promise to keep and a stock that has not given it much credit for making it. Last quarter management issued its first-ever forward adjusted EBITDA outlook, $68 million to $75 million for fiscal 2027, a meaningful step above both the $61.1 million it just delivered and the range it had reaffirmed all last year. The August quarter is the first real checkpoint on that guidance. Shares have fallen to $3.95, far below a 200-day moving average of $6.29, so the market is clearly waiting to see the numbers.

Wall Street expects a loss of $0.18 per share on revenue of about $264.9 million, which would be 26.4% growth from the $209.5 million reported a year ago. That headline growth rate needs context. BrewDog added $51.1 million in the fiscal fourth quarter. If it contributes something similar now, the acquisition alone explains most of the year-over-year increase, and consensus implies an organic business that is roughly flat. Revenue is also expected to slip from the $281.7 million posted last quarter. The loss estimate is far narrower than last quarter's $0.43, though, so the Street is looking for cleaner results rather than faster growth. On EBITDA, a quarter running near an annualized pace of $17 million to $19 million would support the guide. A figure well short of that early in the year would invite questions about the back half.

Beverage is the swing factor. Legacy US beer revenue fell about 17% organically in the fourth quarter, gross margin slipped to 36% from 39%, and management conceded that integration has taken longer than it expected. A new beer chief operating officer was brought in to drive cost savings and rightsizing. This report should show whether those savings are appearing in margins yet. BrewDog is the other half of that story. Management called the deal margin-accretive and pointed to a strong World Cup activation. A full quarter of steady contribution without further working-capital strain would support the thesis that Tilray is turning scale into earnings power. More slippage in legacy beer would weaken it.

Cannabis presents a mixed setup. International cannabis has grown more than 20% for three straight quarters, and Portugal cultivation has scaled to over 30 metric tons annualized. Keeping that streak alive while absorbing roughly $7 million a quarter in price compression is the key test for the segment. Canadian adult-use growth slowed to 3.2% last quarter, and management attributed most of that to reallocating product to international markets rather than to price. Another step down would make that explanation harder to accept. Canadian medical now carries a roughly $4 million annual headwind from Veterans Affairs reimbursement changes. The CC Pharma distribution business, where margins improved to 14% in the fourth quarter, would ideally hold those gains.

Sentiment has cooled, with bullish readings slipping to 3.4% from 7.4% ahead of the prior report. The stock is down 2% since that release while the S&P 500 gained 3.3%. The previous quarter's range, from $9.34 down to $3.80, shows how much rescheduling enthusiasm has drained away. The more than $50 million raised through the at-the-market program during that spike added dilution. Shares now trade near the bottom of their $3.67 to $4.95 post-earnings range, so expectations are modest, but the technical picture offers little cushion if results disappoint.

The central question is whether the more confident tone from last quarter was earned. Tilray has cut net debt to nearly zero and raised its outlook, but free cash flow is still negative and growth relies heavily on acquisitions. A quarter showing stabilizing beer margins, clean BrewDog contribution and continued international strength would keep the $68 million to $75 million target credible. Soft organic trends paired with thin EBITDA would suggest the new guidance was set too high.